Fusion Pharmaceuticals (NASDAQ:FUSN) has received mixed analyst ratings over the past three months, with a notable shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, reflecting an average target of $17.82, which is a 34.8% increase from the previous average of $13.22. This adjustment suggests a positive outlook on Fusion Pharmaceuticals' future market performance. The company, a clinical-stage biopharmaceutical firm focused on developing therapies for cancer, has shown significant revenue growth and a strong net margin, despite a below-average return on assets.